REGENXBIO Inc.
NASDAQ:RGNXBiotechnology
+$0.16 today
- Market cap
- $478.73M
- Beta
- 1.03
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$5.53
Volume 0.96M
Average 1.24M
Returns on capital
REGENXBIO Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-188.7%
avg -47.1%
ROIC
-42.1%
avg -28.4%
ROA
-42.8%
avg -23.6%
Analysis
ROIC is currently the strongest return metric at -42.1% versus its period average of -28.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Curran Simpson | President, Chief Executive Officer & Director | USD 1.07M | 64 | 338.05K | 0.65% |
Patrick J. Christmas | Executive Vice President & Chief Strategy and Legal Officer | USD 944.7K | 55 | 240.69K | 0.47% |
Stephen Pakola | Executive Vice President & Chief Medical Officer | USD 784.97K | 57 | — | — |
Olivier Danos | Executive Vice President & Chief Scientific Officer | USD 770.12K | 68 | 226.35K | 0.44% |
Mitchell Chan | Executive Vice President & Chief Financial Officer | USD 205.31K | 45 | 147.12K | 0.28% |
Shiva G. Fritsch | Chief Communications & People Officer | — | — | — | — |
Jahannaz Dastgir | Clinical Development Lead | — | — | — | — |
Ram Palanki | Executive Vice President & Chief Commercial Officer | — | 50 | — | — |
Craig Malzahn | Executive Vice President of Product Development & Chief Technology Officer | — | 53 | 109.74K | 0.21% |
Nina Hunter | SVP of Global Regulatory Strategy and Quality | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 1, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$949,381.45
Sells
5
$939,970.44
Net Transaction Value
+$9,411.01
Net buying
Most Active
PAKOLA STEVE
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Aug 27, 26Aug 27, 2026 | Ciongoli Gregory Austin Direct | Buy | $499.7K$499,675.89 |
| Aug 26, 26Aug 26, 2026 | Ciongoli Gregory Austin Direct | Buy | $449.7K$449,705.56 |
| Jul 2, 26Jul 2, 2026 | PAKOLA STEVE Direct | Sell | $29.5K$29,476.04 |
| Jul 1, 26Jul 1, 2026 | PAKOLA STEVE Direct | Sell | $472.3K$472,283.50 |
| Jun 29, 26Jun 29, 2026 | PAKOLA STEVE Direct | Sell | $216.5K$216,472.32 |
| May 11, 26May 11, 2026 | PAKOLA STEVE Direct | Sell | $168.7K$168,705.18 |
| Mar 10, 26Mar 10, 2026 | PAKOLA STEVE Direct | Sell | $53K$53,033.40 |
Summary
Insiders reported 2 buys worth $949,381.45 and 5 sells worth $939,970.44 over the last 12 months. That adds up to net buying of $9,411.01. PAKOLA STEVE was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +14.8% | +36.8% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +14.8% over three years. Forward estimates point to Revenue at +36.8% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does REGENXBIO Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about RGNX's management, answered from reported figures.
Who manages RGNX?
REGENXBIO Inc. (RGNX) lists 10 active executives. The top listed executive is Curran Simpson, President, Chief Executive Officer & Director.
Are RGNX insiders buying or selling?
Recent insider activity shows net buying of $25.15M.
Continue the stock analysis
Jump to another research area for this company.